Available Programs > Online On-Demand

Are you prepared to manage influenza in the era of COVID-19? Listen to Dr Paul G. Auwaerter’s and Dr Javeed Siddiqui’s discussion on the challenges of influenza management in the midst of the COVID-19 pandemic. Explore solutions to your questions about best practices to assess influenza via telehealth, strategies for influenza prophylaxis, and selecting antivirals for children, adolescents, and adults, including patients at high risk of influenza complications. Click here to enter this activity: https://learning.freecme.com/a/37397P2C6ABt

The landscape of maintenance treatment options for ovarian cancer has been rapidly expanding and continues to evolve as new data emerge. Maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab has demonstrated improvements in progression-free survival. A recent trial showed that maintenance therapy involving a PARP inhibitor improved overall survival in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In this enduring activity, an expert will examine relevant advances in genetic biomarker testing to individualize therapy, assess recent efficacy and…

In this educational activity, faculty members Nina Delaney Wagner-Johnston, MD, and Seema A. Bhat, MD, review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or relapsed/refractory (R/R) CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond. https://reachmd.com/programs/cme/evolving-landscape-chronic-lymphocytic-leukemia-selecting-and-managing-targeted-therapy/12643/ 

Join Dr Hossein Borghaei and Dr Kurt Schalper in this personalized adaptive learning platform as they share insights into the role of PD-L1 testing to determine the best approach to ICI therapy, current efficacy and safety data for ICI therapies in NSCLC, and how to identify and mitigate immune-related adverse events (irAEs).   Click below to enter this activity: https://spirelearning.realcme.com/learner/course/2828

Are you prepared to accurately assess the severity of atopic dermatitis (AD) across a diverse spectrum of age, comorbidities, and skin of color? Are you aware of the new and emerging targeted therapy options for mild to severe AD and the evolving physiological concepts behind their rationale? The goals of this activity are to educate pediatric and adult dermatologists, allergists, and dermatologic advanced practice providers (APPs) on the diagnosis and assessment of AD and its severity in children, adolescents, and…

Did you miss the Alzheimer’s Association International Conference (AAIC) 2021 Annual Virtual Scientific Meeting? Key advances in the diagnosis and treatment of Alzheimer’s disease (AD) were presented at the AAIC 2021 meeting, including several reports on novel biomarkers for identifying early signs of AD and late-breaking clinical data on approved and emerging treatment strategies. Join Dr Zoe Arvanitakis and Dr Marwan Sabbagh as they share important take-home messages from select abstracts presented at the AAIC 2021 meeting, and access our resource library stocked…

Join Chesahna Kindred, MD, MBA, FAAD, and Jonathan A. Bernstein, MD, as they discuss missed opportunities for the diagnosis, management, and assessment of chronic spontaneous urticaria (CSU) in this interactive learning experience that uniquely mirrors what you may encounter in clinical practice. The activity will present you with a CSU patient receiving suboptimal care and challenge your clinical decision-making skills. https://realcme.realcme.com/learner/course/2854

Join Chesahna Kindred, MD, MBA, FAAD, and Jonathan A. Bernstein, MD, as they discuss missed opportunities for the management and assessment of chronic spontaneous urticaria (CSU) in this interactive learning experience that uniquely mirrors what you may encounter in clinical practice. The activity will present you with a CSU patient with skin of color and challenge your clinical decision-making skills. https://realcme.realcme.com/learner/course/2855    

Looking for an expert-guided roundup of the 14th Clinical Trials on Alzheimer’s Disease (CTAD) and the American Neurological Association (ANA) annual meetings? Dr. Zoe Arvanitakis and Dr. Marwan Sabbagh offer their insights on key findings in the assessment and management of patients with Alzheimer’s disease (AD). Dive into this highly interactive educational activity and access our resource library stocked with video summaries and peer-reviewed articles to get up-to-date on recent advances in novel biomarkers for identifying early signs of AD and…

Did you miss the latest updates on multiple myeloma presented at ASH 2021? Join Dr Faith Davies and Dr Nina Shah as they review late-breaking data on approved and emerging therapies for newly diagnosed multiple myeloma! https://learning.freecme.com/a/38663PA6uG2J  

Dry eye disease is one of the most common ophthalmic complaints; it results from the activity of various pathways and is considered a multifactorial disease. An important factor that contributes to the onset of dry eye disease is meibomian gland dysfunction. Meibomian gland dysfunction causes a disruption in the tear film lipid layer, which affects the rate of tear evaporation. This evaporation leads to tear hyperosmolarity, eventually triggering the onset of dry eye disease. Dry eye disease and meibomian gland…

Join our expert faculty, Chesahna Kindred, MD, MBA, FAAD and Shawn Kwatra, MD, FAAD, as they discuss patient scenarios utilizing methods to avoid missed opportunities for the care team, assess the clinical efficacy and safety of standard off-label, as well as emerging therapies, and ultimately devise effective treatment plans that encourage long-term adherence and address residual disease burden for patients with PN.   Click the link below to access the course: https://realcme.realcme.com/learner/course/2866

Join our expert faculty, Chesahna Kindred, MD, MBA, FAAD and Shawn Kwatra, MD, FAAD, as they discuss patient scenarios utilizing methods to avoid missed opportunities for the care team, assess the clinical efficacy and safety of standard off-label, as well as emerging therapies, and ultimately devise effective treatment plans that encourage long-term adherence and address residual disease burden for patients with PN.   Click the link below to access the course: https://realcme.realcme.com/learner/course/2865

When and how to use specific direct oral anticoagulant (DOAC) reversal agents is not straightforward. Two major professional societies (eg, the American College of Cardiology and the American College of Emergency Physicians ) issued expert panel recommendations for anticoagulant reversal only within the last year. In addition, reports of real-world experience with prothrombin complex concentrates (PCCSs) for DOAC reversal have been published in the recent past, potentially prompted by familiarity with PCCSs to reverse warfarin among other factors. Furthermore, evaluating…

Looking for guidance on who may benefit from calcitonin gene-related peptide (CGRP)-targeted therapies for migraine prevention? Unsure which migraine preventive therapy may be best for your patient? In this CliniClip activity, Drs Jessica Ailani and Susan Hutchinson use real-world patient scenarios to share their expert insights on who may benefit from a CGRP-targeted therapy and highlight when a small molecule or a monoclonal antibody may be appropriate for migraine prevention.   Click the link below to access the course: https://cmepreview.healio.com/neurology/20220207/incorporating-new-therapeutic-tools-for-migraine-prevention-an-expert-guided-discussion/cme-overview …

How does Fabry disease (FD) differ among women and men? Experts Dawn Laney, MS, CGC, CCRC, and Damara Ortiz, MD, FAAP, FACMG, discuss important clinical considerations for women with this lysosomal storage disorder in this 60-minute interactive live webcast. Gender-specific differences in the clinical presentation and diagnostic work-up for FD, current and emerging therapies in the management of FD, and the importance of elevating women in FD research are key points addressed in this activity. Mollie, an adult patient living…

Are you aware of the strong association between dry eye disease (DED) and meibomian gland dysfunction (MGD)? In this 30-minute educational podcast, Dr Eric D. Donnenfeld offers valuable insights on the association of DED and MGD, as well as the evidence-based protocol for clear and accurate diagnosis, and proper disease management, considering new and emerging therapies for DED and MGD.  

Looking for the latest evidence from care guidelines and clinical trials in the management of immunoglobulin A nephropathy (IgAN)? Unsure which of the new and merging therapies may be best to consider for your patient with IgAN? In this E-monograph activity, Dr Mohamed Atta will review the important role of proteinuria in IgAN, and the impact of new and emerging therapies for IgAN to optimize proteinuria lowering in clinical practice and improve patient outcomes.  

Are you up to date on the latest guidance for managing menopause-associated vasomotor symptoms (VMS)? This activity will enable you to gain insights from the experts as they identify factors contributing to VMS, discuss approaches to addressing the undertreatment of VMS, review currently available hormonal and nonhormonal treatments for VMS, explore novel targets and nonhormonal investigational agents for treating VMS, and recognize patients who might be appropriate candidates for novel agents for VMS.     Click the link below to…

Are you up to date with the role of biomarkers for Alzheimer’s disease (AD)? Biomarkers offer a promising path to early detection of AD, assessing drug efficacy, determining drug appropriateness, and even monitoring disease progression. As AD research continues, it is important for clinicians to stay up to date on current and future uses of biomarkers. In this activity, the association between AD and biomarkers and clinical symptoms of AD will be reviewed, the implementation of validated biomarkers for early…

Are you familiar with the role of Janus kinase (JAK) inhibitors for atopic dermatitis (AD)? With over half of patients with AD reporting insufficient disease control, therapeutic management is challenging. In this activity, a dermatology expert explores the rationale behind JAK inhibition for the treatment of AD, clinical trial data on JAK inhibitors for AD, and considering JAK inhibitors when determining patient-specific management of this complex disease.     Click the link below to access the course: https://www.rapidcme.com/activity.aspx?actID=94  

Are you familiar with the impact of mental health disorders on outcomes for patients with multiple sclerosis (MS)? Join neuropsychiatry expert Jonathan Howard, MD, in this case-based educational activity focused on educating clinicians on the impact of depression and other mental health disorders on patients with MS, identifying opportunities for care collaboration in MS management, and creating patient-specific care strategies for patients with MS to optimize treatment regimens.     Click the link below to access the course: https://cme.healio.com/neurology/ace-the-case/20220923/improving-mental-health-in-patients-with-ms-to-positively-impact-adherence-and-outcomes/overview